Marquee industry conference will showcase data
from CBR's Newborn Possibilities Program®
TRUMBULL, Conn., Sept. 8,
2023 /PRNewswire/ -- CooperSurgical, a global leader
in fertility and women's health, announced that Cord Blood
Registry® (CBR®) will have a key role in the
upcoming Cord Blood Connect meeting from September 8th – 11th, which
is the annual meeting of the Cord Blood Association. The Cord Blood
Association is an international nonprofit organization that
promotes both public and family newborn stem cell preservation and
accelerates the use of cord blood and birthing tissues to
benefit patients and advance medicine.
"Cord Blood Connect is a critical meeting for public and family
cord blood banks, allowing them a forum to discuss industry
innovations, patient needs, and evolving industry standards,"
stated Holly Sheffield, President,
CooperSurgical. "We are proud to be the Platinum Sponsor of this
event, and to be presenting new scientific data, as well as
moderating a forum with key industry voices to discuss the future
of cord blood banking. Our presence and participation is one
example of CooperSurgical's commitment to elevating this
industry."
CBR's abstract titled "Experience with enrollments and releases
within a medical needs program at a large U.S. private cord blood
bank" was accepted as a poster presentation at Cord Blood Connect.
The objective of the study was to examine indications for
enrollments and unit releases in CBR's Newborn Possibilities
Program. Through this program, CBR offers free cord blood and
tissue processing and five years of storage for families with
a qualifying medical need. The results of the study suggested
the structure of the Newborn Possibilities Program is effective in
identifying families who have a higher likelihood of utilizing
their cord blood unit for a transplant or experimental infusion.
The investigators also noted that cord blood banks should continue
to re-evaluate the eligibility criteria for their medical needs
program in light of relevant updates in the potential utility of
newborn stem cells including changes in transplant medicine
indications and treatment procedures, as well as clinical trials
and experimental protocols using related cord blood units. Future
research related to pathways of referral to medical needs programs
may inform education gaps among women's health providers.
"We're delighted to see our Newborn Possibilities Program being
highlighted as a poster presentation at Cord Blood Connect,"
commented Peter Bawin, Global Vice
President, Commercial Life Sciences, CooperSurgical. "This program
was designed with families in mind, especially if a specific health
history indicated a medical need that may potentially be treated
using newborn stem cells. As the largest private newborn stem cell
company in the world, we are happy to take the lead in finding ways
to expand access to more families, especially as the science
continues to evolve around this area of medicine."
Mr. Bawin will be moderating a panel titled "Future of Cord
Blood Banking" on Saturday, September
9th featuring global leaders from the major
family and public cord blood banks. The panel will discuss
challenges facing the industry, along with the opportunities that
exist given the changing landscape in hematopoietic transplant and
the growing field of cell therapies. It also plans to explore how
cord blood banks can be proactive in shaping the future of the
industry.
For more information about Cord Blood Connect and CBR's
participation, please visit
https://www.cb-association.org/cord-blood-connect.
About CBR by CooperSurgical
Cord Blood Registry® (CBR®) is the
largest private newborn stem cell company in the world, helping
parents store stem cells from cord blood and cord tissue for their
children. Founded in 1994, CBR is the #1 choice for
parents1 and most recommended by OB/GYNs for newborn
stem cell preservation.2 The company has released
over 700 samples intended for use in transplant medicine and
regulated investigational regenerative medicine applications. CBR
is here to help expand the possibilities of what newborn stem cell
therapies can do for families and give parents the confidence to
Bank on CBR™. More information can be found
at www.cordblood.com.
About CooperSurgical
CooperSurgical® is a
leading fertility and women's healthcare company dedicated to
putting time on the side of women, babies, and families at the
healthcare moments that matter most in life. CooperSurgical is at
the forefront of delivering innovative assisted reproductive
technology and genomic solutions that enhance the work of ART
professionals to the benefit of families. We currently offer over
600 clinically relevant medical devices to women's healthcare
providers, including testing and treatment options.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies
(NYSE: COO). CooperSurgical, headquartered in Trumbull,
CT, produces and markets a wide array of products and services for
use by women's health care clinicians. More information can be
found at www.coopersurgical.com.
About CooperCompanies
CooperCompanies ("Cooper") is a
global medical device company publicly traded on the NYSE (NYSE:
COO). Cooper operates through two business units, CooperVision and
CooperSurgical. CooperVision brings a refreshing perspective on
vision care with a commitment to developing a wide range of
high-quality products for contact lens wearers and providing
focused practitioner support. CooperSurgical is committed to
advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of
more than 15,000 with products sold in over 130 countries. For more
information, please visit www.coopercos.com.
Disclaimer:
The use of cord blood is determined by the
treating physician and is influenced by many factors, including the
patient's medical condition, the characteristics of the sample, and
whether the cord blood should come from the patient or an
appropriately matched donor. Cord blood has established uses in
transplant medicine; however, its use in regenerative medicine is
still being researched. There is no guarantee that potential
medical applications being studied in the laboratory or clinical
trials will become available.
Cord tissue use is still in early research stages, and there is
no guarantee that treatments using cord tissue will be available in
the future. Cord tissue is stored whole. Additional processing
prior to use will be required to extract and prepare any of the
multiple cell types from cryopreserved cord tissue. Cbr Systems,
Inc.'s activities for New York
State residents are limited to collection of umbilical cord
tissue and long-term storage of umbilical cord–derived stem cells.
Cbr Systems, Inc.'s possession of a New
York State license for such collection and long-term storage
does not indicate approval or endorsement of possible future uses
or future suitability of these cells.
References:
- Internal source. Data on file.
- Blind survey, Egg Strategy, 10/19, funded by CBR.
Contact:
CooperSurgical
EvolveMKD
csi@evolvemkd.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cord-blood-registry-announces-thought-leadership-role-at-cord-blood-connect-301922405.html
SOURCE CooperSurgical®
